Sign up to The Irish Times Archive (1859 - 2008)My Account »
Wed 01 Jan 2009Biotech Elan may go on market after strategic review
IRISH BIOTECH group Elan may put itself on the market as a result of a strategic review announced yesterday. The company said advisers will assess a range of options to provide the funds and commercial structure to develop its drug pipeline and maximise the potential of existing products.
The news came on the same day that Biogen Idec, its partner in the Tysabri programme, revealed that sales of the multiple sclerosis (MS) drug had slowed sharply towards the end of last year.
Choose a Subscription type - required
